Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebecsinib in Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis
NCT07250646Phase 1Recruiting
- Sponsor
- Aspera Biomedicines, Inc.
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rebecsinib in acute myeloid leukemia (AML) and myelofibrosis (MF), sponsored by Aspera Biomedicines, Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Treatment-Emergent Adverse Events at 4 months. Started May 2026; status: recruiting.
02
Drugs
rebecsinib
03
Conditions
acute myeloid leukemia (AML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07250646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250646.